HHS awards $53.2M contract for pandemic vaccine egg supply, raising questions on competition and value

Contract Overview

Contract Amount: $53,212,199 ($53.2M)

Contractor: Sanofi Vaccines US Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2025-02-01

End Date: 2027-01-31

Contract Duration: 729 days

Daily Burn Rate: $73.0K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: Healthcare

Official Description: MAINTAINING OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE

Place of Performance

Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $53.2 million to SANOFI VACCINES US INC. for work described as: MAINTAINING OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE Key points: 1. Contract awarded on a non-competitive basis, limiting price discovery and potentially increasing costs. 2. The fixed-fee structure may incentivize cost overruns if not closely monitored. 3. Long contract duration (729 days) could lock in potentially suboptimal pricing. 4. The biological product manufacturing sector is critical for public health preparedness. 5. Dependence on a single supplier for a critical pandemic resource presents supply chain risks. 6. The contract's value is significant within the context of vaccine production readiness.

Value Assessment

Rating: questionable

The contract's value is difficult to assess without competitive benchmarks. The 'COST PLUS FIXED FEE' (CPFF) contract type, while common for R&D and uncertain scope, can lead to higher costs than fixed-price contracts if not managed diligently. The fixed fee component is 15% of the estimated cost, which is within typical ranges, but the overall cost-effectiveness hinges on the efficiency of the contractor's operations and the government's oversight. Benchmarking against similar contracts for biological product manufacturing, especially those related to vaccine components, is challenging due to the specialized nature of embryonated egg supply for pandemic preparedness.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. The justification for this approach is not provided in the data, but typically such awards are made when only one responsible source is available or in cases of urgent and compelling need. The lack of competition means that the government did not explore potential alternative suppliers or negotiate pricing against a competitive landscape, which could lead to a higher price than if multiple bids were solicited.

Taxpayer Impact: Sole-source awards limit the government's ability to secure the best possible price, potentially resulting in taxpayer funds being used less efficiently. It also bypasses the market's natural price discovery mechanisms.

Public Impact

The primary beneficiaries are public health agencies relying on a stable supply of pandemic vaccine components. The contract ensures the availability of embryonated eggs, a critical input for producing certain types of vaccines. This supports national biodefense and pandemic preparedness efforts. The contract's geographic impact is primarily within Pennsylvania, where the contractor is located, but its ultimate impact is national in ensuring vaccine readiness.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition raises concerns about potential overpayment and reduced value for taxpayer money.
The sole-source nature limits transparency in pricing and contractor selection.
Reliance on a single supplier for a critical component could pose supply chain risks.
The CPFF contract type requires robust government oversight to control costs effectively.

Positive Signals

Ensures a critical supply chain component for pandemic vaccine production.
The contractor is likely experienced in biological product manufacturing, suggesting a degree of reliability.
The contract duration provides stability for a vital public health resource.

Sector Analysis

The contract falls within the Biological Product (except Diagnostic) Manufacturing sector, a critical component of the broader healthcare and life sciences industry. This sector is characterized by high R&D investment, stringent regulatory requirements, and significant government procurement for public health initiatives, particularly in areas like vaccine development and biodefense. The market size for vaccine production inputs is substantial, driven by both routine healthcare needs and emergency preparedness. This contract represents a specific, albeit crucial, niche within that market, focusing on a foundational element for vaccine manufacturing.

Small Business Impact

This contract does not appear to have a small business set-aside component (ss=false, sb=false). Given the specialized nature of biological product manufacturing for pandemic preparedness, it is likely that larger, established firms are better positioned to meet the requirements. There is no explicit information on subcontracting plans for small businesses, which could be an area for further inquiry to ensure opportunities are maximized within the broader ecosystem.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). As a Cost Plus Fixed Fee contract, rigorous financial oversight and performance monitoring by the government are essential to manage costs and ensure the contractor meets all deliverables. Transparency would be enhanced by public reporting of contract performance and expenditures. The specific Inspector General jurisdiction would be that of HHS.

Related Government Programs

Pandemic Preparedness Programs
Vaccine Manufacturing Support
Biodefense Initiatives
National Stockpile Maintenance
Public Health Emergency Response

Risk Flags

Sole-source award lacks competitive justification.
Potential for suboptimal pricing due to lack of competition.
Supply chain risk associated with single-source dependency.
CPFF contract requires diligent cost oversight.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $53.2 million to SANOFI VACCINES US INC.. MAINTAINING OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE

Who is the contractor on this award?

The obligated recipient is SANOFI VACCINES US INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $53.2 million.

What is the period of performance?

Start: 2025-02-01. End: 2027-01-31.

What is the specific justification for awarding this contract on a sole-source basis?

The provided data does not include the specific justification for the sole-source award. Typically, sole-source contracts are justified under circumstances such as urgent and compelling needs where only one responsible source can provide the required product or service, or when a unique capability is required that cannot be obtained from multiple sources. For a critical supply like embryonated eggs for pandemic vaccines, the justification might relate to specialized production capabilities, existing infrastructure, or the time constraints associated with developing a new pandemic vaccine supply chain. Without the official justification document, it is difficult to definitively assess the necessity of the sole-source approach.

How does the fixed fee component of this CPFF contract compare to industry standards for similar services?

The data indicates a 'fixed fee' (ff) value, but not its percentage relative to the estimated cost. However, the contract type is 'COST PLUS FIXED FEE' (CPFF). In CPFF contracts, the contractor is reimbursed for all allowable costs plus a fixed fee representing profit. The fixed fee is negotiated at the outset and does not change, regardless of the final cost. Industry standards for fixed fees in CPFF contracts can vary widely, often ranging from 5% to 15% of the estimated cost, depending on the complexity, risk, and nature of the work. Without knowing the specific fixed fee amount or percentage negotiated for this contract, a direct comparison to industry standards is not possible. However, the government's negotiation process aims to secure a fee that is fair and reasonable.

What are the potential risks associated with relying on a single supplier for embryonated eggs for pandemic vaccine production?

Relying on a single supplier for a critical component like embryonated eggs for pandemic vaccine production introduces several significant risks. Firstly, there is a supply chain vulnerability; any disruption at the supplier's facility (e.g., due to disease outbreak, natural disaster, labor issues, or operational failure) could halt vaccine production. Secondly, the lack of competition inherent in a sole-source relationship can lead to less favorable pricing and potentially reduced incentives for the supplier to innovate or maintain the highest quality standards. Thirdly, if the supplier's capabilities degrade or they face financial difficulties, the government may have limited alternatives for a rapid transition, potentially delaying critical public health responses during a crisis.

What is the historical spending pattern for maintaining embryonated egg supply for pandemic vaccine production by HHS?

The provided data snippet focuses on a single contract award and does not offer historical spending patterns for this specific requirement. To analyze historical spending, one would need to query federal procurement databases (like FPDS or USASpending) for similar contracts awarded by HHS or other relevant agencies over several fiscal years. This would involve searching for contracts with keywords related to 'embryonated eggs,' 'vaccine production,' 'pandemic preparedness,' and relevant Product Service Codes (PSCs) or North American Industry Classification System (NAICS) codes. Such an analysis would reveal trends in contract values, durations, award types (competitive vs. sole-source), and contractor performance over time.

How does the duration of this contract (729 days) impact the government's flexibility and potential cost savings?

A contract duration of 729 days (approximately two years) provides stability and ensures a consistent supply of embryonated eggs for pandemic vaccine production over a significant period. This long duration can be beneficial for planning and maintaining readiness. However, it also reduces the government's flexibility to adapt to changing market conditions, technological advancements, or new supplier capabilities that might emerge during the contract term. From a cost perspective, a longer duration can sometimes lead to better pricing through economies of scale or longer-term commitments. Conversely, if market prices decrease or more efficient production methods become available, the government might be locked into a less favorable price for the remainder of the contract term.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing

Product/Service Code: MEDICAL SERVICES › OTHER MEDICAL SERVICES

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Sanofi

Address: 1 DISCOVERY DR, SWIFTWATER, PA, 18370

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $79,838,515

Exercised Options: $53,212,199

Current Obligation: $53,212,199

Actual Outlays: $17,184,386

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline